Allen J Weiss1, Marta Lorente-Ros2, Ashish Correa3, Nitin Barman3, Jacqueline E Tamis-Holland4. 1. Divison of Cardiology, Bronxcare Health System, Division of Cardiology, Mount Sinai Morningside Hospital and the Ichan School of Medicine at Mount Sinai, New York, NY, USA. 2. Department of Medicine, Mount Sinai Morningside and Mount Sinai West Hospitals and the Ichan School of Medicine at Mount Sinai, New York, NY, USA. 3. Division of Cardiology, Mount Sinai Morningside Hospital and the Ichan School of Medicine at Mount Sinai, New York, NY, USA. 4. Division of Cardiology, Mount Sinai Morningside Hospital and the Ichan School of Medicine at Mount Sinai, New York, NY, USA. Jacqueline.Tamis-Holland@mountsinai.org.
Abstract
PURPOSE OF REVIEW: Drug-eluting stents are used in nearly all cases of percutaneous coronary revascularization and have been shown to be superior to balloon angioplasty or bare metal stents. The designs of these stents are continually evolving to maximize efficacy and safety. RECENT FINDINGS: This review outlines the important components of a drug-eluting stent and highlights the changes in stent design that have led to the optimization of clinical outcomes. Most stents used in contemporary times are thin strut, durable polymer drug-eluting stents (DES) that elute either everolimus or zotarolimus. Newer DES designs incorporating bioresorbable polymers or ultrathin struts have shown encouraging safety and efficacy profiles. DES are essential for the management of patients with obstructive coronary artery disease and are used in most coronary interventions. Changes in stent designs over the past 30 years reflect the ongoing need to address the limitations of earlier stents aimed to improve patient outcomes.
PURPOSE OF REVIEW: Drug-eluting stents are used in nearly all cases of percutaneous coronary revascularization and have been shown to be superior to balloon angioplasty or bare metal stents. The designs of these stents are continually evolving to maximize efficacy and safety. RECENT FINDINGS: This review outlines the important components of a drug-eluting stent and highlights the changes in stent design that have led to the optimization of clinical outcomes. Most stents used in contemporary times are thin strut, durable polymer drug-eluting stents (DES) that elute either everolimus or zotarolimus. Newer DES designs incorporating bioresorbable polymers or ultrathin struts have shown encouraging safety and efficacy profiles. DES are essential for the management of patients with obstructive coronary artery disease and are used in most coronary interventions. Changes in stent designs over the past 30 years reflect the ongoing need to address the limitations of earlier stents aimed to improve patient outcomes.
Authors: R Hoffmann; G S Mintz; G R Dussaillant; J J Popma; A D Pichard; L F Satler; K M Kent; J Griffin; M B Leon Journal: Circulation Date: 1996-09-15 Impact factor: 29.690
Authors: P W Serruys; P de Jaegere; F Kiemeneij; C Macaya; W Rutsch; G Heyndrickx; H Emanuelsson; J Marco; V Legrand; P Materne Journal: N Engl J Med Date: 1994-08-25 Impact factor: 91.245
Authors: D R Holmes; R E Vlietstra; H C Smith; G W Vetrovec; K M Kent; M J Cowley; D P Faxon; A R Gruentzig; S F Kelsey; K M Detre Journal: Am J Cardiol Date: 1984-06-15 Impact factor: 2.778
Authors: D L Fischman; M B Leon; D S Baim; R A Schatz; M P Savage; I Penn; K Detre; L Veltri; D Ricci; M Nobuyoshi Journal: N Engl J Med Date: 1994-08-25 Impact factor: 91.245
Authors: Marie-Claude Morice; Patrick W Serruys; J Eduardo Sousa; Jean Fajadet; Ernesto Ban Hayashi; Marco Perin; Antonio Colombo; G Schuler; Paul Barragan; Giulio Guagliumi; Ferenc Molnàr; Robert Falotico Journal: N Engl J Med Date: 2002-06-06 Impact factor: 91.245
Authors: R A Schatz; D S Baim; M Leon; S G Ellis; S Goldberg; J W Hirshfeld; M W Cleman; H S Cabin; C Walker; J Stagg Journal: Circulation Date: 1991-01 Impact factor: 29.690